-
公开(公告)号：US12188947B2
公开(公告)日：2025-01-07
申请号：US17293946
申请日：2019-11-05
Inventor： Goo Taeg Oh , Sejin Jeon , Tae Kyeong Kim , Yangsoo Jang , Sung-Jin Hong , Hye-Young Yun
Abstract: The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.
-
公开(公告)号：US20220026443A1
公开(公告)日：2022-01-27
申请号：US17293946
申请日：2019-11-05
Inventor： Goo Taeg Oh , Sejin Jeon , Tae Kyeong Kim , Yangsoo Jang , Sung-Jin Hong , Hye-Young Yun
Abstract: The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.
-
Search Results
2
records
(took 0.011 seconds)
